aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:…
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 17, 2026 18:22 ET | Source: BridgeBio Pharma, Inc. PALO ALTO,…
FundaMental Pharma to showcase groundbreaking approach to treatment-resistant depression at Bio-Neuroscience Conference
Presentation will highlight lead clinical candidate FMP374, a novel dual-acting NMDAR modulator…
Vistin Pharma ASA: Fourth quarter and preliminary 2025 financial results
Oslo, Norway, 12th of February 2026 Vistin Pharma ASA (VISTN) today announces…
‘Made in India – The story of Desh Bandhu Gupta, Lupin and Indian Pharma’ Book Launched in Mumbai
MUMBAI, India, Feb. 9, 2026 /PRNewswire/ -- Made in India, written by…
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2026 16:01 ET | Source: NewAmsterdam Pharma N.V. NAARDEN, The…
CORRECTING and REPLACING — BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
January 27, 2026 17:10 ET | Source: BridgeBio Pharma, Inc. PALO ALTO,…
Nxera Pharma Reports Positive Results From Phase 3 Trial of Daridorexant in South Korea
Daridorexant is a dual orexin receptor antagonist being developed by Nxera for…
Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference
Two commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine growth with strong…
Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference
- Rapidly transforming into a leading global biopharma company January 09, 2026…
